Yesterday, the U.S. Court of Appeals for the Federal Circuit issued a precedential ruling in Regeneron Pharmaceuticals ... by properly specifying which accused products infringed the asserted ...

Yesterday, the U.S. Court of Appeals for the Federal Circuit issued a precedential ruling in Regeneron Pharmaceuticals ... by properly specifying which accused products infringed the asserted ...

It's not the first time AZ has been accused of infringing Opdivo's patents. Earlier this month, Ono Pharmaceutical sued the UK drugmaker saying Imfinzi infringes a Japanese patent on Opdivo ...

Previously, Regeneron accused Amgen of infringing on multiple patents related to Eylea while developing its biosimilar, and Regeneron sought a preliminary injunction to halt Pavblu’s launch. However, ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Regeneron reported Q4 2024 earnings today - revenues were up 10% YoY to $3.79bn. Full-year revenues were up 8% to $14.2bn. Q4 GAAP EPS at $8.06, and $38 adj. full-year. The company declared its ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

As for revenue, Regeneron reported it at $3.79 billion for the fourth quarter, which was up 10% year over year. The company's full-year haul came in at $14.2 billion, which was an increase of 8%.

Regeneron has started 2025 with an increase in defensive capital allocation - initiation of a dividend and an expanded share buyback program. Increased competitive pressure on the Eylea franchise ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The ...